Express News | 23andMe Holdings: 23Me-00610 monotherapy continues to demonstrate acceptable safety and tolerability.

Breakings20:02

Express News | Tumor Cd200 is becoming a potential biomarker associated with the efficacy of the single therapy 23Me-00610 in 23Andme Holding Co.

Breakings20:02

Express News | 23Andme Holding Co.: Tumor Cd200 Is Emerging as a Potential Biomarker Associated With 23Me-00610 Monotherapy Efficacy

Breakings20:02

Express News | 23Andme Holding Co.: 23Me-00610 Monotherapy Continues to Demonstrate Acceptable Safety and Tolerability

Breakings20:02

Express News | 23Andme Holding Co.: 23Me-00610 Monotherapy Demonstrates Preliminary Evidence of Clinical Benefit, Including One Confirmed Partial Response

Breakings20:02

Express News | 23Andme Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23Me-00610, Targeting Cd200R1, at the 2024 Asco Annual Meeting

Breakings20:00